Environmental, Social, and Governance (ESG) Programs will be Subject to Increased Scrutiny

Key Takeaways

• ESG programs are under enhanced scrutiny as investors and regulators probe questions such as diversity in clinical trials, access to healthcare and drug pricing, and the environmental impact of drugs and their packaging.
• The U.S. Securities and Exchange Commission (SEC) has recently begun to actively use its powers to push for ESG disclosure, with two new proposed rules.
• Two EU directives will have a major impact on life sciences companies’ ESG programs.

View Article